Biology and clinical impact of human natural killer cells

Sherif Farag, Jeffrey B. VanDeusen, Todd A. Fehniger, Michael A. Caligiuri

Research output: Contribution to journalArticle

78 Citations (Scopus)

Abstract

Natural killer (NK) cells, through elaboration of cytokines and cytolytic activity, are critical to host defense against invading organisms and malignant transformation. Two subsets of human NK cells are identified according to surface CD56 expression. CD56dim cells compose the majority of NK cells and function as effectors of natural cytotoxicity and antibody-dependent cellular cytotoxicity, whereas CD56bright cells have immunomodulatory function through secretion of cytokines. For a long time, NK cells have held promise for cancer immunotherapy because, unlike T-lymphocytes, NK cells can lyse tumor cells without tumor-specific antigen recognition. To date, NK cell therapy, largely focused on in vivo expansion and activation with cytokines, has met with only modest success. However, recent understanding of the importance of NK receptors (NKR) for recognition and lysis of tumor cells while normal cells are spared suggests novel therapeutic strategies. The balance of inhibitory and activating signals through surface receptors that recognize major histocompatibility complex class I and class I-like molecules on target cells determines whether NK cells activate killing. Identification of NKR ligands and their level of expression on normal and neoplastic cells has important implications for the rational design of immunotherapy strategies for cancer. We review recent development in the biology and clinical relevance of NK cells in cancer immunotherapy.

Original languageEnglish (US)
Pages (from-to)7-17
Number of pages11
JournalInternational Journal of Hematology
Volume78
Issue number1
StatePublished - Jul 2003
Externally publishedYes

Fingerprint

Natural Killer Cells
Immunotherapy
Neoplasms
Cytokines
Neoplasm Antigens
Cell- and Tissue-Based Therapy
Major Histocompatibility Complex
Ligands
T-Lymphocytes
Antibodies

Keywords

  • ADCC
  • IL-15
  • IL-2
  • Immunotherapy
  • NK cells

ASJC Scopus subject areas

  • Hematology

Cite this

Farag, S., VanDeusen, J. B., Fehniger, T. A., & Caligiuri, M. A. (2003). Biology and clinical impact of human natural killer cells. International Journal of Hematology, 78(1), 7-17.

Biology and clinical impact of human natural killer cells. / Farag, Sherif; VanDeusen, Jeffrey B.; Fehniger, Todd A.; Caligiuri, Michael A.

In: International Journal of Hematology, Vol. 78, No. 1, 07.2003, p. 7-17.

Research output: Contribution to journalArticle

Farag, S, VanDeusen, JB, Fehniger, TA & Caligiuri, MA 2003, 'Biology and clinical impact of human natural killer cells', International Journal of Hematology, vol. 78, no. 1, pp. 7-17.
Farag S, VanDeusen JB, Fehniger TA, Caligiuri MA. Biology and clinical impact of human natural killer cells. International Journal of Hematology. 2003 Jul;78(1):7-17.
Farag, Sherif ; VanDeusen, Jeffrey B. ; Fehniger, Todd A. ; Caligiuri, Michael A. / Biology and clinical impact of human natural killer cells. In: International Journal of Hematology. 2003 ; Vol. 78, No. 1. pp. 7-17.
@article{d1a3da6686e747ec9032b7ccd5180da3,
title = "Biology and clinical impact of human natural killer cells",
abstract = "Natural killer (NK) cells, through elaboration of cytokines and cytolytic activity, are critical to host defense against invading organisms and malignant transformation. Two subsets of human NK cells are identified according to surface CD56 expression. CD56dim cells compose the majority of NK cells and function as effectors of natural cytotoxicity and antibody-dependent cellular cytotoxicity, whereas CD56bright cells have immunomodulatory function through secretion of cytokines. For a long time, NK cells have held promise for cancer immunotherapy because, unlike T-lymphocytes, NK cells can lyse tumor cells without tumor-specific antigen recognition. To date, NK cell therapy, largely focused on in vivo expansion and activation with cytokines, has met with only modest success. However, recent understanding of the importance of NK receptors (NKR) for recognition and lysis of tumor cells while normal cells are spared suggests novel therapeutic strategies. The balance of inhibitory and activating signals through surface receptors that recognize major histocompatibility complex class I and class I-like molecules on target cells determines whether NK cells activate killing. Identification of NKR ligands and their level of expression on normal and neoplastic cells has important implications for the rational design of immunotherapy strategies for cancer. We review recent development in the biology and clinical relevance of NK cells in cancer immunotherapy.",
keywords = "ADCC, IL-15, IL-2, Immunotherapy, NK cells",
author = "Sherif Farag and VanDeusen, {Jeffrey B.} and Fehniger, {Todd A.} and Caligiuri, {Michael A.}",
year = "2003",
month = "7",
language = "English (US)",
volume = "78",
pages = "7--17",
journal = "International Journal of Hematology",
issn = "0925-5710",
publisher = "Springer Japan",
number = "1",

}

TY - JOUR

T1 - Biology and clinical impact of human natural killer cells

AU - Farag, Sherif

AU - VanDeusen, Jeffrey B.

AU - Fehniger, Todd A.

AU - Caligiuri, Michael A.

PY - 2003/7

Y1 - 2003/7

N2 - Natural killer (NK) cells, through elaboration of cytokines and cytolytic activity, are critical to host defense against invading organisms and malignant transformation. Two subsets of human NK cells are identified according to surface CD56 expression. CD56dim cells compose the majority of NK cells and function as effectors of natural cytotoxicity and antibody-dependent cellular cytotoxicity, whereas CD56bright cells have immunomodulatory function through secretion of cytokines. For a long time, NK cells have held promise for cancer immunotherapy because, unlike T-lymphocytes, NK cells can lyse tumor cells without tumor-specific antigen recognition. To date, NK cell therapy, largely focused on in vivo expansion and activation with cytokines, has met with only modest success. However, recent understanding of the importance of NK receptors (NKR) for recognition and lysis of tumor cells while normal cells are spared suggests novel therapeutic strategies. The balance of inhibitory and activating signals through surface receptors that recognize major histocompatibility complex class I and class I-like molecules on target cells determines whether NK cells activate killing. Identification of NKR ligands and their level of expression on normal and neoplastic cells has important implications for the rational design of immunotherapy strategies for cancer. We review recent development in the biology and clinical relevance of NK cells in cancer immunotherapy.

AB - Natural killer (NK) cells, through elaboration of cytokines and cytolytic activity, are critical to host defense against invading organisms and malignant transformation. Two subsets of human NK cells are identified according to surface CD56 expression. CD56dim cells compose the majority of NK cells and function as effectors of natural cytotoxicity and antibody-dependent cellular cytotoxicity, whereas CD56bright cells have immunomodulatory function through secretion of cytokines. For a long time, NK cells have held promise for cancer immunotherapy because, unlike T-lymphocytes, NK cells can lyse tumor cells without tumor-specific antigen recognition. To date, NK cell therapy, largely focused on in vivo expansion and activation with cytokines, has met with only modest success. However, recent understanding of the importance of NK receptors (NKR) for recognition and lysis of tumor cells while normal cells are spared suggests novel therapeutic strategies. The balance of inhibitory and activating signals through surface receptors that recognize major histocompatibility complex class I and class I-like molecules on target cells determines whether NK cells activate killing. Identification of NKR ligands and their level of expression on normal and neoplastic cells has important implications for the rational design of immunotherapy strategies for cancer. We review recent development in the biology and clinical relevance of NK cells in cancer immunotherapy.

KW - ADCC

KW - IL-15

KW - IL-2

KW - Immunotherapy

KW - NK cells

UR - http://www.scopus.com/inward/record.url?scp=0041846486&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0041846486&partnerID=8YFLogxK

M3 - Article

C2 - 12894845

AN - SCOPUS:0041846486

VL - 78

SP - 7

EP - 17

JO - International Journal of Hematology

JF - International Journal of Hematology

SN - 0925-5710

IS - 1

ER -